Viridian appoints Jennifer Moses, CPA to board and as Audit Committee Chair

Viridian Therapeutics, Inc.\DE

Appointed Jennifer Moses as Class II director and Chair of Audit Committee, effective July 14, 2021.
Moses serves as CFO of G1 Therapeutics (GTHX) since 2019; previously partner at Rankin McKenzie.
Receives $55k annual cash retainer; granted option for 25,000 shares at July 14 closing price, vesting over 3 years.
CPA with B.S. in Accounting from Penn State; held roles at Deloitte including strategic planning.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jennifer K. Moses

Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2021-07-14
Filed: July 15, 2021, 7:59 PM ET

On July 14, 2021, the board of directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) appointed Jennifer K. Moses as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer K. Moses was appointed as Director at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Director

Exact text from the filing

On July 14, 2021, the board of directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) appointed Jennifer K. Moses as a member of the Board.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-21-216388

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.